

Available online at www.sciencedirect.com





EJSO 40 (2014) 875-882



www.ejso.com

Impact of radical operative treatment on the quality of life in women with vulvar cancer - A retrospective study

V. Günther^a, B. Malchow^b, M. Schubert^a, L. Andresen^a, A. Jochens^c, W. Jonat^a, C. Mundhenke^a, I. Alkatout^{a,*}

^aDepartment of Gynecology and Obstetrics, University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House 24, 24105 Kiel, Germany ^bReference Center for Quality of Life, University Hospitals Schleswig-Holstein, Campus Kiel,

Arnold-Heller Str. 3, House 18, 24105 Kiel, Germany

^c Institute of Medical Informatics and Statistics, University Hospitals Schleswig-Holstein, Campus Kiel,

Brunswiker Str. 10, 24105 Kiel, Germany

Accepted 27 March 2014 Available online 3 April 2014

Abstract

Objectives: For patients undergoing vulva surgery the quality of life (QoL) is generally accepted as an important outcome parameter in addition to long-term survival, mortality and complication rates. Less radical operative treatment can reduce morbidity and thereby improve quality of life. This study focuses on outcome in terms of QoL in patients comparing wide local excision (WLE) with radical vulvectomy and waiver of lymphonodectomy (LNE) with inguinofemoral lymphonodectomy.

Methods: In a retrospective single-center study from 2000 to 2010, 199 patients underwent surgery for vulvar cancer. To assess QoL, the EORTC QLQ-C30 and a tumor-specific module questionnaire were sent to all patients in the follow-up period.

Results: Women who underwent WLE have a superior QoL with regard to global health status and physical, role, emotional and cognitive functioning than those who underwent radical vulvectomy. Less radical surgery also implies less fatigue, nausea/vomiting, pain, insomnia, appetite loss, diarrhea and financial difficulties. After radical vulvectomy 89% of patients have sexual complications.

Conclusion: Radical operative treatment, such as radical vulvectomy, causes deterioration in the QoL of these patients. An individualized, less radical surgery must be the aim in the treatment of vulvar cancer.

© 2014 Elsevier Ltd. All rights reserved.

Keywords: Vulvar cancer; Quality of life; Radical vulvectomy; Lymphonodectomy; EORTC QLQ-C30; Disease free survival; Overall survival

Introduction

Vulvar cancer is the fourth most common gynecologic cancer (following cancer of the uterine corpus, ovary and cervix) and comprises five percent of malignancies of the female genital tract.¹ Vulvar cancer most frequently occurs in women between 65 and 75 years of age²; however, an increase in vulvar cancer has been noted over the past decade, especially in younger women (35–65 years of age), attributable to human papillomavirus (HPV) infection.^{3,4} Surgical resection is the gold standard of treatment and should completely remove the tumor. Initially, radical vulvectomy with bilateral lymphonodectomy (LNE) was recommended as the standard treatment for most patients. Currently, a more individualized and less radical surgery (wide local excision (WLE)) instead of vulvectomy and sentinel lymph node biopsy (SLN) instead of LNE is recommended to minimize surgery-related morbidity, such as lymphedema, painful legs or recurrent erysipelas. The pT(NM) classification and the associated surgery is given in Table 1. Fig. 1 shows the standard of LNE.

Besides basic data on morbidity, mortality and survival, the quality of life (QoL) is generally accepted as an additional outcome parameter in patients undergoing oncologic surgery. Quality of life is a multidimensional concept which is defined as a person's view of life and his/her satisfaction with life.^{5,6} QoL for patients is defined as "the extent to

^{*} Corresponding author. Tel.: +49 431 597 2100.

E-mail addresses: ibrahim.alkatout@uksh.de, kiel.school@uksh.de (I. Alkatout).

^{0748-7983/\$ -} see front matter © 2014 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.ejso.2014.03.027

| Table 1 | |
|---|--|
| Staging vulvar cancer, TNM and International Federation of Gynecology and Obstetrics, FIGO. | |

Primary tumor (T)

| TNM categories | FIGO stages | Definition | Surgery |
|----------------------|-------------|--|---|
| TX | | Primary tumor cannot be assessed | |
| Τ0 | | No evidence of primary tumor | |
| Tis | | Carcinoma in situ | WLE, no LNE |
| T1a N0 M0 | IA | Lesions 2 cm or less in size, confined to the | WLE, no LNE |
| | | vulva or perineum and with stromal invasion | |
| | | 1.0 mm or less | |
| T1b N0 M0 | IB | Lesions more than 2 cm size or any size with | WLE, (SLN) LNE ipsilateral |
| | | stromal invasion more than 1.0 mm, confined to | |
| | | the vulva or perineum | |
| T2/T3 N0 M0 | II | Tumor of any size with extension to adjacent perineal | Modified radical vulvectomy |
| | | structures (lower/distal 1/3 urethra, lower/distal 1/3 | (hemivulvectomy, anterior or |
| | | vagina, anal involvement) | posterior vulvectomy), (SLN) LNE bilateral |
| T3 N0 or T1-T3 N1 M0 | Ш | Tumor of any size with or without extension to adjacent | Modified radical or radical |
| | 111 | perineal structures (lower third of urethra/vagina/anus) | vulvectomy with inguinal and |
| | | with positive inguinofemoral nodes | femoral node dissection. |
| | | will positive inguilorenteral nodes | Radiation therapy to the pelvis |
| T1/T2/T3 N1a/N1b M0 | IIIA | With 1 lymph node metastasis (>5 mm) or with $1-2$ | |
| | | lymph node metastases (<5 mm) | |
| T1/T2/T3 N2a/N2b M0 | IIIB | With 2 or more lymph node metastases (≥ 5 mm) or with | |
| | | 3 or more lymph node metastases (<5 mm) | |
| T1/T2/T3 N2c M0 | IIIC | With positive nodes with extracapsular spread | |
| T4 N0 - N2 M0 | IVA | Tumor of any size with extension to any of the following: | Neoadjuvant chemoradiation and |
| | | upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder | selected surgery, no LNE |
| | | mucosa, rectal mucosa or fixed to pelvic bone | |
| any T any N M1 | IVB | Tumor has spread to distant organs or lymph nodes | Neoadjuvant chemoradiation and |
| | | | selected surgery, no LNE |

which one's usual or expected physical, emotional and social well-being is affected by a medical condition or its treatment." For cancer patients, most of these aspects of life are influenced negatively.^{7–10} Furthermore, it has been reported that the measurement of QoL has prognostic value in patients with oncologic diseases.^{11,12} Vulvectomy, as well as inguinal and pelvic LNE, severely affects the physical, emotional and social health of patients and has highly negative consequences for the patient's short and long-term quality of life. Furthermore, the treatment of vulvar cancer permeates the most intimate and sensitive region of the affected women.^{13,14}

In this study we examined the QoL in patients with vulvar cancer using a valid cancer-specific questionnaire with a




Figure 1. Standard of LNE in patients with vulvar cancer.

Download English Version:

https://daneshyari.com/en/article/3985240

Download Persian Version:

https://daneshyari.com/article/3985240

Daneshyari.com